KKM-181C is under clinical development by Kolmar Korea and currently in Phase I for Idiopathic (Essential) Hypertension. According to GlobalData, Phase I drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the KKM-181C LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KKM-181C overview
KKM-181C is under development for the treatment of idiopathic (essential) hypertension. It is an incrementally modified drug. It is administered by oral route.
Kolmar Korea overview
Kolmar Korea (Kolmar Korea), a subsidiary of Kolmar Group AG, develops, manufactures, and markets cosmetics, pharmaceuticals, and health functional foods. The company’s product portfolio comprises of skin care products, make up products, body and hair care products, perfumes, makeup products such as cream, lotion eye liner, lip stick, shampoo, sunscreen, hand care, nail, and pedicure products. Kolmar Korea’s pharmaceutical products include prescription drugs, dermatology and circulatory system, over-the-counter drugs, bioequivalent drug and quasi drugs. It provides health supplements such as health booster, cholesterol reducer, blood circulation protectors, and special purpose food including weight control food, meal replacement food and sport nutrition food. Kolmar Korea is headquartered in Sejong, South Korea.
For a complete picture of KKM-181C’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
